Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Recruiting 5Terminated 2Suspended 2Completed 2

Sponsor Class

OTHER 1NIH 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2Other solid neoplasm 2Lymphoid 1Gynecologic 1Endocrine 1

Conditions

Neoplasm Metastasis 5Colorectal Neoplasms 5Breast Neoplasms 5Neoplasms 4Multiple Myeloma 4Carcinoma, Non-Small-Cell Lung 4Prostatic Neoplasms 3Leukemia, Myeloid, Acute 3Carcinoma, Hepatocellular 3Uterine Cervical Neoplasms 2Triple Negative Breast Neoplasms 2Solid Tumor 2Sarcoma 2Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 2Pancreatic Neoplasms 2Ovarian Neoplasms 2Osteosarcoma 2Mesothelioma, Malignant 2Melanoma 2Lymphoma, T-Cell 2Lung Neoplasms 2Immunoblastic Lymphadenopathy 2Glioblastoma 2Carcinoma, Renal Cell 2Carcinoma 2Biliary Tract Neoplasms 2Urinary Bladder Neoplasms 1Spinal Diseases 1Spinal Cord Neoplasms 1Solid Tumors 1

Interventions

decitabine and cedazuridine drug combination 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Suspended × Mesothelioma, Malignant × 30 days × Clear all
NCT05337735 2026-05-04

A Phase II Clinical Trial to Evaluate Safety and Efficacy of XmAb20717 in Advanced Rare Cancers

M.D. Anderson Cancer Center

Phase 2 Suspended
140 enrolled
EndocrineGynecologicLymphoidOther solid neoplasmThoracic

Mesothelioma, Malignant, Uterine Cervical Neoplasms, Hodgkin Disease, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

NCT05960773 2026-05-04

Decitabine/Cedazuridine (INQOVI), an Oral DNA Demethylating Agent, in Subjects With BAP1 Cancer Predisposition Syndrome and Subclinical, Early-Stage Mesothelioma

National Institutes of Health Clinical Center (CC)

Phase 2 Suspended
9 enrolled
Other solid neoplasmThoracic

Mesothelioma, Malignant, Mesothelioma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡